Balance Sheets (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Current assets
Cash and cash equivalents	$ 236,079	$ 4,304
Prepaid expenses and other current assets	2,096	44
Other Assets		331
Security deposits	158	158
Total current assets	238,333	4,837
Property, plant and equipment, net	32	42
Other long term assets	11
Total assets	238,376	4,879
Current liabilities
Accrued clinical drug supplies and trial costs	3,477	1,013
Accounts payable and accrued expenses	4,431	1,391
Notes payable		11,040
Warrant liability		966
Total current liabilities	7,908	14,410
Royalty purchase liability	41,667
Total liabilities	49,575	14,410
Stockholders' equity (deficit)
Common stock - $0.001 par value, 200,000,000 shares authorized, 31,250,817 shares issued and outstanding at September 30, 2013; 155,864,851 shares authorized, 1,469,798 shares issued and outstanding at December 31, 2012	31	1
Additional paid-in capital	351,431
Deficit accumulated during development stage	(162,661)	(126,471)
Total stockholders' equity (deficit)	188,801	(123,470)
Total liabilities and stockholders' equity (deficit)	238,376	4,879
Convertible and redeemable preferred stock
Preferred Stock, Convertible and Redeemable:
Total Preferred Stock, Convertible and Redeemable		113,939
Series A
Preferred Stock, Convertible and Redeemable:
Total Preferred Stock, Convertible and Redeemable		69,471
Series A-1
Preferred Stock, Convertible and Redeemable:
Total Preferred Stock, Convertible and Redeemable		8,460
Series B
Preferred Stock, Convertible and Redeemable:
Total Preferred Stock, Convertible and Redeemable		35,456
Series B-1
Preferred Stock, Convertible and Redeemable:
Total Preferred Stock, Convertible and Redeemable		552
Junior Series A Convertible Preferred Stock
Stockholders' equity (deficit)
Preferred Stock		3,000
Preferred stock
Stockholders' equity (deficit)
Preferred Stock